+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice



Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice



Pain 153(2): 342-349



Understanding the effect of herpes zoster and zoster-related pain should inform care to improve health-related quality of life in elderly patients. A 12-month, longitudinal, prospective, multicenter observational study conducted in primary care in France enrolled patients aged ≥ 50 years with acute eruptive herpes zoster. Patient-reported zoster-related pain was assessed by validated questionnaires (Douleur Neuropathique en 4 Questions [DN4], Zoster Brief Pain Inventory [ZBPI], and Neuropathic Pain Symptom Inventory [NPSI]) on days 0 and 15, and at months 1, 3, 6, 9, and 12. Health-related quality of life was assessed by the 12-item short-form health survey (SF-12) and the Hospital Anxiety and Depression scale on day 0 and at months 3, 6, and 12. Of 1358 patients included, 1032 completed follow-up. Mean ± standard deviation age was 67.7 ± 10.7 (range, 50-95) years; 62.2% were women. Most patients (94.1%) were prescribed antiviral drugs. The prevalence of zoster-related pain on day 0 and at months 3, 6, 9, and 12 was 79.6%, 11.6%, 8.5%, 7.4%, and 6.0%, respectively. Patients with persistent pain had lower scores on the physical and mental component summaries of the SF-12 and the ZBPI interference score than those without pain. By logistic regression analysis, main predictive factors on day 0 for postherpetic neuralgia at month 3 were age, male sex, ZBPI interference score, Physical Component Summary score of the SF-12, and neuropathic quality of pain (DN4 score ≥ 4). Despite early diagnosis and treatment with antiviral agents, many patients with herpes zoster experience persistent pain and marked long-term reduction in health-related quality of life.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054888789

Download citation: RISBibTeXText

PMID: 22138256

DOI: 10.1016/j.pain.2011.10.026


Related references

Patient perspective on herpes zoster and its complications an observational prospective study in patients aged over 5 years in general practice. 2011

A cross-sectional study of the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting. Hong Kong Medical Journal 23(4): 365-373, 2017

Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. Journal of Dermatology (): -, 2016

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study. Clinical Drug Investigation 38(1): 29-37, 2018

Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. Bmc Infectious Diseases 14(): 637-637, 2015

Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. International Journal of Std & Aids 16(10): 673-676, 2005

Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study. Journal of Epidemiology 25(10): 617-625, 2016

Australian zoster study: GP and patient views about herpes zoster (shingles), its complications, and the likely acceptance of a zoster vaccine (Zostavax). International Journal of Infectious Diseases 21: 436-437, 2014

Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs 73(11): 1227-1244, 2014

Shingles Herpes Zoster Vaccine ZostavaxA A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged a 50A Years. 2013

The detection, diagnosis, and impact of cognitive impairment among inpatients aged 65 years and over in an Irish general hospital - a prospective observational study. International Psychogeriatrics 29(11): 1879-1888, 2017

Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan. Drugs - Real World Outcomes 4(4): 187-198, 2017

Herpes zoster (shingles) at a large New Zealand general practice: incidence over 5 years. New Zealand Medical Journal 127(1407): 56-60, 2014

Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. Journal of Geriatric Oncology 10(4): 637-642, 2019

Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study. Bmj Open 6(10): E011539, 2016